BSE filing, NSE: SBILIFE. Summary written from the filing by ALFA Finder's alert engine.
SBI Life Insurance Company Ltd: key numbers
- Share price
- ₹1,767.00
- Market cap
- ₹1,77,302 Cr
- Revenue (annual)
- ₹1,12,315 Cr
- Net profit (annual)
- ₹2,470 Cr
- P/E (TTM)
- 66.8×Sector 20.8×
- Promoter holding
- 55.31%-0.01% QoQ
- FII holding
- 20.68%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from SBI Life Insurance Company Ltd
All →SBI Life Insurance Company Management Change
SBI Life Insurance has issued a postal ballot notice seeking shareholder approval for appointing Mr. Nihar Niranjan Jambusaria as an Independent Director. Voting ends 3 December 2026.
SBI Life Insurance Company Annual General Meeting
SBI Life issued a postal ballot notice seeking member approval to appoint Mr. Nihar Jambusaria as Independent Director for three years. E-voting runs from November 4 to December 3, 2026.
- Execution
- September 22, 2026 to September 21, 2029
SBI Life Insurance Company Earnings Call Transcript: Key Takeaways
SBI Life delivered a strong 19% growth in Value of New Business (VNB) and margin expansion, effectively managing a one-time ₹530 Cr GST impact while maintaining market leadership.
- Call
- Guides 14% growth
SBI Life Insurance Company Results Update
SBI Life's H1 FY27 profit after tax rose 17% to ₹12.7 billion. Gross written premium grew 13% and the solvency ratio is 1.97.
SBI Life Insurance Company Q2 FY27 Results: Net Profit ₹549.2 Cr, Up 11.0% YoY
SBI Life Insurance Company Ltd reported revenue from operations of ₹26,878 Cr (+8.2% YoY) and net profit of ₹549.2 Cr (+11.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹549.2 Cr · +11.0% YoY
SBI Life Insurance Company Board Meeting Date
SBI Life scheduled a board meeting on October 27, 2026, to consider and approve financial results for the quarter and half year ended September 30, 2026.
Other regulatory approval announcements
All →Sandur Manganese & Iron Ores Regulatory Approval
Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.
- iron ore RoM capacity
- 9.42 MTPA
Neogen Chemicals Regulatory Approval
Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.
Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.